Get the Stockscreener App
10.51
0.65%
-0.069
Agomab Therapeutics Nv Adr stock is traded at $10.51, with a volume of 456.
It is down -0.65% in the last 24 hours and down -25.03% over the past month.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
See More
Previous Close:
$10.58
Open:
$10.65
24h Volume:
456
Relative Volume:
0.00
Market Cap:
$524.49M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-15.63
EPS:
-0.6724
Net Cash Flow:
-
1W Performance:
-13.63%
1M Performance:
-25.03%
6M Performance:
-18.27%
1Y Performance:
+0.00%
1-Day Range:
$10.65
$10.65
1-Week Range:
$10.50
$12.26
52-Week Range:
$8.75
$17.82
Agomab Therapeutics Nv Adr Stock (AGMB) Company Profile
Name
Agomab Therapeutics Nv Adr
Sector
Industry
Phone
-
Address
-
Compare AGMB vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGMB
Agomab Therapeutics Nv Adr
|
10.65 | 521.04M | 0 | 0 | 0 | -0.6724 |
VRTX
Vertex Pharmaceuticals Inc
|
521.37 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.46 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.13 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
960.68 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.17 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agomab Therapeutics Nv Adr Stock (AGMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-03-26 | Initiated | JP Morgan | Overweight |
| Mar-03-26 | Initiated | Leerink Partners | Outperform |
| Mar-03-26 | Initiated | Morgan Stanley | Overweight |
Agomab Therapeutics Nv Adr Stock (AGMB) Latest News
Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL) and AgomAb Therapeutics NV ADR (AGMB) - The Globe and Mail
AgomAb Therapeutics Director Patel Naimish Receives Derivative Securities Award Equaling 100% of Holdings - Kalkine Media
AgomAb Therapeutics Director Marino Garcia Granted 57,482 Stock Options - Kalkine Media
Agomab Moves Inhaled IPF Drug AGMB-447 Into Phase 2 After Positive Phase 1 Results - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Agomab Shareholders Approve New Board Members and Pre-IPO Warrant Adjustment - TipRanks
ETFs Investing in AgomAb Therapeutics NV ADR Stocks - TradingView
Analysts Have Conflicting Sentiments on These Healthcare Companies: PROCEPT BioRobotics (PRCT), Invivyd (IVVD) and Alpha Tau (DRTS) - The Globe and Mail
This Agomab Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
Analysts Offer Insights on Healthcare Companies: Fortrea Holdings Inc. (FTRE), AgomAb Therapeutics NV ADR (AGMB) and Sana Biotechnology (SANA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), Talphera (TLPH) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Lakefront Biotherapeutics (LKFT), Prime Medicine, Inc. (PRME) and Electrocore (ECOR) - The Globe and Mail
Agomab Proposes New Board Members and Plans Warrant Adjustment Ahead of September 11 Meetings - TipRanks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: NRX Pharmaceuticals (NRXP), Novo Nordisk (NVO) and Pfizer (PFE) - The Globe and Mail
Agomab Posts Half-Year 2026 Results, Advances Fibro-Inflammation Pipeline After Nasdaq IPO - TipRanks
Analysts Are Bullish on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Beam Therapeutics (BEAM) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Precision BioSciences (DTIL) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE), BrightSpring Health Services, Inc. (BTSG) and AgomAb Therapeutics NV ADR (AGMB) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: Annexon Biosciences (ANNX), uniQure (QURE) - The Globe and Mail
B.Riley initiates Agomab Therapeutics stock with buy rating - Investing.com India
B. Riley Initiates AgomAb Therapeutics at Buy With $34 Price Target - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), COMPASS Pathways (CMPS) and Alkermes (ALKS) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP) and Mettler-Toledo (MTD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
AGMBAgomAb Therapeutics NV ADR Short Interest - Finviz
AgomAb Therapeutics NV ADR Actuals & Estimates (NASDAQ:AGMB) - TradingView
AGMB Forecast — Price Target — Prediction for 2027 - TradingView
Agomab announces Phase 2b study design for Crohn’s disease drug - Investing.com
Form 6K Agomab Therapeutics Nv For: 23 June By Investing.com - Investing.com India
This Apple Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday - Sahm
This Credo Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Sahm
H.C. Wainwright initiates Agomab stock coverage with buy rating - Investing.com
Agomab Announces Results of Annual General Meeting - GlobeNewswire Inc.
Why AgomAb (AGMB) is a smarter play than most realize (Drops Hard) 2026-05-08BPI Bear Correction - The Legal Advocate
Double BottomStock ScreenerCharts - Finviz
Agomab Posts 2025 Loss, Fortifies Cash After IPO and Targets Key 2026 Trial Milestones - The Globe and Mail
AgomAb (NASDAQ: AGMB) posts €62.5m loss and funds operations into 2029 - Stock Titan
AGMB Technical Analysis | Trend, Signals & Chart Patterns | AGOMAB THERAPEUTICS NV (NASDAQ:AGMB) - ChartMill
United Health Group, Viacom among market cap stock movers on Tuesday - Investing.com
World Map - Finviz
Reviewing Prime Medicine (NASDAQ:PRME) and AgomAb Therapeutics (NASDAQ:AGMB) - Defense World
Agomab receives U.S. patent for lung fibrosis drug candidate By Investing.com - Investing.com India
Agomab receives U.S. patent for lung fibrosis drug candidate - Investing.com
What is the current Price Target and Forecast for AgomAb Therapeutics NV (AGMB) - Zacks Investment Research
EQT Life Sciences-Backed AgomAb Falls After $200 Million IPO - Livemint
AgomAb Therapeutics NVADR (AGMB) sentiment score, message volume, participation score and buzz level - Stocktwits
AGMB: AgomAb Therapeutics NVADR Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
AgomAb Therapeutics NV American Depositary Shares (AGMB) Stock Price Today: $13.51 - Gotrade
EQT Life Sciences-Backed AgomAb Falls 8% After $200 Million IPO - Bloomberg
AgomAb Therapeutics NV (AGMB) stock price, news, quote and history - Yahoo Finance UK
Agomab Therapeutics Nv Adr Stock (AGMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):